Bayer to support Harvard Research Study to evaluate trust in science, including in COVID-19 pandemic

BayerWith the public debate on the merits of scientific data throughout the COVID-19 pandemic, Bayer announced its support for a new, multi-year Harvard Data Science Initiative (HDSI) research effort. This initiative will explore the public engagement with science, and better understand how to build confidence in the reliability, capability and integrity of scientific data and sound science.

"Scientific progress is essential to solve the pressing challenges of our time," said Werner Baumann, Chief Executive Officer at Bayer. "We are honored to join the Harvard Data Science Initiative’s efforts to evaluate the best ways to strengthen public dialogue around science and empower future evidence-based innovation. The acceptance of science is critical for human progress."

The HDSI Research Fund for Trust in Science supports the advancement of trust in science through data-driven, actionable insights. The first HDSI undertaking will be to study the public response to scientists and scientific findings in the wake of COVID-19, with other trust in science topics addressed in the future. These findings can guide future activities that strengthen the role of science and facts in decision making. Bayer has committed to support this multi-year research initiative with a total of one million US dollars.

"While scientists have emerged as visible advisors during the COVID-19 pandemic, a public debate has emerged about the value and validity of scientific research as nations evaluate the next steps in their recovery," said Monika Lessl, Head of Corporate R&D, Social Innovation at Bayer and Executive Director of the Bayer Foundation. "Therefore, we will work with the HDSI to evaluate the successes of and learnings from scientific communication during the pandemic's early months and identify opportunities to further improve the delivery of scientific data and insights among key audiences."

Established in 2017, the HDSI coalesces activity in statistics, computer science, and diverse fields of application to advance data science methodologies and apply them to questions of societal importance and impact. Through its Corporate Membership Program, the HDSI connects leading global organizations with Harvard’s broad data science ecosystem to create opportunities for long-term scientific, economic, and social progress. Bayer joined the program in January 2020.

"Public trust in science is fundamental to our ability to change the world for the better, whether in academia, government, non-profit or industry," said Francesca Dominici, co-Director of the HDSI and Clarence James Gamble Professor of Biostatistics, Population and Data Science at the Harvard T.H. Chan School of Public Health. "We are fortunate to have a partner like Bayer who is committed to thinking creatively and holistically about how data can illuminate the path toward a healthier future."

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros.

About Harvard Data Science Initiative

The Harvard Data Science Initiative was launched in 2017 to connect data science efforts across Harvard University's numerous schools and research centers. It combines and coordinates diverse technical and domain expertise to ignite moonshot initiatives and drive scientific, economic, and social progress. Through its research and education initiatives the HDSI revolutionizes and amplifies data-driven approaches to creating new knowledge for the world.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...